Platelet aging and removal

Aging and platelet removal . Typically plateletscirculate 8 to 10 days in a number ranging from 140,000 to 400,000 cells / uL. 30% of circulating platelets are sequestered by the mononuclear phagocytic system (SFM), especially the spleen. The disappearance of platelets from the circulation, either as part of a physiological aging process or as a manifestation of increased destruction, has been the subject of intense research. The survival of platelets in the circulation can be studied using different techniques; the most accepted is the labeling of a platelet sample with a radioactive isotope (51Cr or 111In), which is reinjected and the disappearance of radioactivity over time is measured. Survival curves, obtained with this technique, under normal conditions have shown a disappearance of radioactivity that follows a linear type function;

Summary

[ hide ]

  • 1 Aging of platelets in the circulation
  • 2 Density
  • 3 Platelet membrane
  • 4 Physiological removal of platelets
  • 5 Immune mechanism of platelet removal
  • 6 Non-immune platelet removal mechanisms
  • 7 Source

Aging of platelets in the circulation

During aging in the circulation, platelets undergo a series of physical, biochemical and functional changes that significantly determine their heterogeneity. Of the wide variety of changes demonstrated during platelet aging, some have been better characterized, and it has even been suggested that they may represent markers of their age. Among these, it is important to analyze changes in density, granular content and membrane structures, as representative of three compartments of platelets that undergo changes with age in the circulation.

Density

Although the heterogeneity of platelet density is largely determined at the bone marrow level during megakaryopoiesis, as they age in the circulation they change in density in a sense that depends on the species under study. Thus, human platelets and some primate species increase in density with age.

In canines, rabbits, and rhesus monkeys, platelet density decreases with age. Since the change in platelet density with age is dependent on the species studied, the results obtained in other species cannot be extrapolated to analyze the relationship between the physical heterogeneity of human platelets and their age in circulation. Knowing the density / age relationship of circulating platelets in different species is very useful from an experimental point of view, since it gives the possibility of studying platelets of different ages at steady state.

As for the behavior of dense granules with aging in human and canine platelets, the content of serotonin (5-Hydroxytryptamine) increases with the age of the platelets in the circulation, implying a process of in vivo accumulation of the amine. This change is also useful experimentally, as it can be used as a platelet age marker.

Platelet membrane

At the platelet membrane level, it has been observed that low-density human platelets, enriched with young platelets, express 55% more HLA class I antigens than high-density platelets, which are, on average, older. These observations suggest that the antigens of this system could be lost with the wear and aging of platelets in the circulation. Loss of other membrane glycoproteins (GPIIb-IIIa) has not been demonstrated with aging.

The expression of CD36 (GPIV) and the exposure of CD62P (P-selectin) do not show differences in human high-density (PAD) and low-density platelet (PBD) subpopulations, which allows us to conclude that they do not change significantly with the age of platelets in the circulation. On the other hand, in aged platelets, increased expression of phosphatidylserine (FS) and increased platelet-associated IgG (PAIgG) have been described.

Physiological removal of platelets

Some alterations or changes described in platelets that age in the circulation, although they are unequivocal age markers (eg density, 5-HT), do not seem to be determinants of the removal of cells from the circulation. The macrophages of the SFM (spleen and liver and to a lesser extent of the bone marrow) must detect changes associated with platelet aging that trigger their removal. The two proposed mechanisms for the removal of aged cells in other systems will be summarized here: non-immune mechanism and immune mechanism.

Immune mechanism of platelet removal

PAIgG increases with age of platelets in the circulation. The evidence is based on:

  • The human high-density platelet (PAD) subpopulation, enriched with older platelets, express higher PAIgG than the low-density platelet (PBD) subpopulation, enriched with young platelets.
  • The canine PBD subpopulation (older average age), express higher PAIgG than the PAD subpopulation, and (c) in the thrombopoiesis suppression model, in which platelets that age in vivo are obtained, PAIgG increased progressively with age. platelets in circulation.

Possibly this is explained by the appearance of the neoepitope (s) in some of the membrane proteins, which could be associated with the binding of natural antibodies. A similar phenomenon has been described in red blood cells ; the erythrocytes senescent express a neoepitope in protein band 3. studying the specificity of antiplatelet autoantibodies (that explain the increased platelet paigc aged), it was observed that:

  • Platelets do not express band 3, so this protein would not participate in the physiological platelet removal mechanism, as it does in erythrocytes.
  • Another neoantigen, described in platelets aged in vitro, expressed by GPIIb-IIIa (epitope of antibody 5E5), also does not seem to play a relevant role.

As an experimental demonstration of the immune removal mechanism, it was observed that fresh platelets sensitized with anti-PlA1 antibody showed a greater interaction with monocytes stimulated (by IFNγ), than non-sensitized ones. In both types of platelets a small percentage of these exposed FS and PAIgG was significantly higher in the sensitized ones. Said interaction was inhibited by blocking the FcγR of the monocytes with purified IgG. Furthermore, apparently the receptor for complement fragments, CR2 would not participate in the physiological removal of platelets.

Nonimmune platelet removal mechanisms

FS exposure increases in aged platelets; This is based on the following evidence: (a) a higher percentage of human PADs than PBDs, exposes FS, (b) circulating aged dog platelets expose more FS than young platelets, and (c) human PADs present a greater quantity. of Ca2 +. FS exposure is one of the early manifestations of apoptosis, preceding DNA fragmentation (in nucleated cells) and loss of membrane integrity. Nuclear changes are often viewed as a hallmark or mark of programmed cell death or apoptosis; however, in nucleated cells, such as platelets, it apparently would not be an indispensable element as an initiating event. Platelets may be capable of undergoing changes similar to those observed in apoptotic events in nucleated cells. Platelets appear to contain molecular components of apoptosis that are involved at the cytoplasmic level. Platelets aged in vitro show loss of phospholipid asymmetry and activation of caspase 3. Furthermore, it has been described that in vivo aging of platelets is associated with activation of apoptosis, finding that their mitochondria undergo important changes in the The integrity of its membrane, before a classic signal of apoptosis, such as FS exposure, is observed.

As experimental evidence of interaction through the non-immune mechanism, it has been observed that platelets stored for more than 6 days (Blood Bank platelet concentrate) show greater interaction with stimulated monocytes than fresh platelets. In both types of platelets the PAIgG was normal and the FS expression was significantly higher in the stored ones.

Said interaction was inhibited with FS liposomes and with anti-CD36 monoclonal antibody. All these observations allow us to postulate that in the phenomenon of physiological removal of aged platelets from circulation, more than one mechanism would participate: (a) immune mechanism explained by the increase in autologous PAIgG on aged platelets that promotes interaction with FcγR of monocytes, and (b) non-immune mechanism, in which FS exposure on the outer surface of the membrane of aging platelets (by apoptosis), with the participation of the CD36 receptor and eventually another receptor that recognizes phospholipids as its ligand natural.

 

Leave a Comment

Scroll to Top